Pacific Biosciences of California, Inc. (PACB)

NASDAQ: PACB · Real-Time Price · USD

1.280

-0.070 (-5.19%)

At close: Aug 24, 2026, 4:00 PM EDT

1.310

+0.030 (2.34%)

Pre-market: Aug 25, 2026, 5:27 AM EDT

PACB Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	61	63.71	55.37	179.91	325.09	460.73
Short-Term Investments	175.87	215.8	334.56	451.51	447.23	583.68
Cash & Short-Term Investments	236.87	279.51	389.93	631.42	772.32	1,044
Cash Growth	-24.74%	-28.32%	-38.25%	-18.24%	-26.05%	227.59%
Accounts Receivable	31.1	35.45	27.52	36.62	18.79	24.24
Receivables	31.1	35.45	27.52	36.62	18.79	24.24
Inventory	61.08	49.29	58.76	56.68	50.38	24.6
Prepaid Expenses	9.55	10.79	18.78	17.04	10.29	7.39
Restricted Cash	0.03	0.02	0.69	0.3	0.3	0.5
Total Current Assets	338.64	375.05	495.68	742.05	852.07	1,101
Property, Plant & Equipment	67.3	65.84	46.6	69.03	81.34	79.12
Goodwill	317.76	317.76	317.76	462.26	409.97	409.97
Other Intangible Assets	13.08	15.12	389.57	456.98	410.25	410.98
Other Long-Term Assets	15.06	10.31	10.84	15.7	13.45	5.76
Total Assets	751.85	784.08	1,260	1,746	1,767	2,007

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	19.22	20.77	16.59	15.06	12.03	11
Accrued Expenses	18.91	26.98	21.51	44.74	34.58	39.27
Current Portion of Long-Term Debt	3	-	-	0.49	1.84	1.61
Current Portion of Leases	1.37	0.45	10.03	9.59	8.89	7.71
Current Unearned Revenue	16.1	15.94	13.86	16.34	30.5	10.98
Other Current Liabilities	10.2	8.7	4.31	8.8	175.5	1.15
Total Current Liabilities	68.81	72.83	66.3	95.03	263.34	71.71
Long-Term Debt	644.33	645.38	647.49	892.24	896.68	896.07
Long-Term Leases	60.42	56.59	14.91	31.61	41.07	49.97
Long-Term Unearned Revenue	3.34	3.93	5.9	5.53	1.79	25.05
Other Long-Term Liabilities	8.16	-	19.25	20.3	1.3	173.19
Total Liabilities	785.06	778.73	753.85	1,045	1,204	1,216

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.31	0.3	0.29	0.27	0.23	0.22
Additional Paid-In Capital	2,715	2,700	2,655	2,540	2,100	2,010
Retained Earnings	-2,748	-2,695	-2,149	-1,839	-1,532	-1,218
Comprehensive Income & Other	-0.5	0.46	0.42	0.22	-4.77	-1.09
Shareholders' Equity	-33.21	5.35	506.59	701.3	562.9	790.99
Total Liabilities & Equity	751.85	784.08	1,260	1,746	1,767	2,007

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	709.13	702.42	672.43	933.93	948.48	955.36
Net Cash (Debt)	-472.25	-422.92	-282.5	-302.51	-176.16	89.05
Net Cash Growth	-	-	-	-	-	-67.83%
Net Cash Per Share	-1.55	-1.41	-1.03	-1.19	-0.78	0.44
Filing Date Shares Outstanding	310.83	302	297.85	267.95	247.08	221.18
Total Common Shares Outstanding	310.81	301.96	294.42	267.74	226.51	220.98
Working Capital	269.83	302.22	429.38	647.02	588.74	1,029
Book Value Per Share	-0.11	0.02	1.72	2.62	2.49	3.58
Tangible Book Value	-364.06	-327.54	-200.74	-217.94	-257.32	-29.97
Tangible Book Value Per Share	-1.17	-1.08	-0.68	-0.81	-1.14	-0.14
Machinery	-	70.17	69.13	68.03	60.86	49.8
Construction In Progress	-	5.41	2.28	1.34	4.7	2.3
Leasehold Improvements	-	33.84	33.77	35.23	34.13	31.11
Order Backlog	-	49.2	58.6	-	-	-

SEC Filings: 10-K · 10-Q